Street Calls of the Week
Tango Therapeutics Inc. (TNGX) has reached a new 52-week high, with its stock price climbing to 9.69 USD. According to InvestingPro data, the company’s remarkable performance includes a 30% surge in the past week alone, with analysts setting price targets ranging from $8 to $13. This milestone reflects a significant upward trend for the company, which has experienced a remarkable 643% increase over the past six months. The biotech firm, focused on developing targeted cancer therapies, has seen its shares steadily rise, driven by positive investor sentiment and advancements in its research and development efforts. With a market capitalization of $1.06 billion and a "Fair" financial health rating from InvestingPro, which offers 14 additional valuable insights about TNGX, the latest high underscores the market’s confidence in Tango Therapeutics’ potential for growth and innovation in the healthcare sector.
In other recent news, Tango Therapeutics has announced the upcoming resignation of its Chief Legal and Compliance Officer, Douglas Barry. Barry will leave his position on September 12, 2025, to pursue another opportunity. The company did not disclose any details regarding his successor. Additionally, Piper Sandler has initiated coverage on Tango Therapeutics with an Overweight rating. The research firm has set a price target of $11.00 for the company. Piper Sandler’s positive outlook is influenced by growing investor confidence in the synthetic lethality space and promising data for Tango’s PRMT5-inhibitor. These developments reflect ongoing changes and assessments within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.